


## microRNA-200c/141 upregulates SerpinB2 to promote breast cancer cell metastasis and reduce patient survival


### SUPPLEMENTARY FIGURES AND TABLES




Supplementary Figure 1: Real-time RT-PCR analysis of miR-200c and miR-141 in MDA-MB-231<sup>miR-200c/141</sup> cells. miR-200c and miR-141 levels were significantly higher in MDA-MB-231<sup>miR-200c/141</sup> cells relative to control (n=3). \*\*\* $P < 0.0001$ .




**Supplementary Figure 2: miR-200c/141 indirectly increased SerpinB2 by regulating SerpinB2 transcription factors and miRNAs.** Real-time RT-PCR showed higher levels of c-Jun, c-Fos and FosB in MDA-MB-231<sup>miR-200c/141</sup> cells compared to controls (A) Western blotting showed increased nuclear localization of p-c-Jun in MDA-MB-231<sup>miR-200c/141</sup> cells compared to controls (B) CAT reporter assay revealed increased SerpinB2 promoter activity in MDA-MB-231<sup>miR-200c/141</sup> cells compared to controls (C) miR-124a and miR-26b were downregulated in MDA-MB-231<sup>miR-200c/141</sup> cells compared to controls (D) \* $P < 0.05$ .




**Supplementary Figure 3: Real-time RT-PCR analysis of SerpinB2, c-Jun, c-Fos, miR-200c, miR124a and miR-26b and western blot of SerpinB2 in MCF-7<sup>miR-200c/141</sup>, Hs578T<sup>miR-200c/141</sup>, and HCC38<sup>miR-200c/141</sup> cells. (A) A significant increase in miR-200c levels was observed in MCF-7<sup>miR-200c/141</sup>, Hs578T<sup>miR-200c/141</sup>, and HCC-38<sup>miR-200c/141</sup> cells compared to controls. SerpinB2 mRNA was downregulated in MCF-7<sup>miR-200c/141</sup>, Hs578T<sup>miR-200c/141</sup>, and HCC-38<sup>miR-200c/141</sup> cells. (B) SerpinB2 protein levels increased in only MDA-MB-231<sup>miR-200c/141</sup> cells relative to control. (C) c-Jun and c-Fos mRNA levels significantly decreased in MCF-7<sup>miR-200c/141</sup>, Hs578T<sup>miR-200c/141</sup>, and HCC-38<sup>miR-200c/141</sup> cells. miR-124a significantly decreased in only MCF-7<sup>miR-200c/141</sup> cells but increased in Hs578T<sup>miR-200c/141</sup> and HCC-38<sup>miR-200c/141</sup> cells compared to controls.**




**Supplementary Figure 4: SerpinB2 knockdown suppressed MDA-MB-231 cell migration promoted by miR200c/141 cluster overexpression.** Representative wound-healing assay images of control and MDA-MB-231<sup>miR-200c/141</sup> cells transfected with SerpinB2 or scramble siRNA (A) Lateral migration of control (n=3), control+scramble (n=3), control+si-SerpinB2 (n=3), MDA-MB-231<sup>miR-200c/141</sup> (n=3), MDA-MB-231<sup>miR-200c/141</sup>+scramble (n=3), and MDA-MB-231<sup>miR-200c/141</sup>+si-SerpinB2 cells (n=3) (B) \**P*<0.05.



**Supplementary Figure 5: Macrophages and fibroblasts associated with MDA-MB-231 xenografts and primary TNBC patient tumors overexpressed SerpinB2.** Macrophage and fibroblast populations overexpressing SerpinB2 were observed at or near the tumor border in xenografts and TNBC patient samples.



**Supplementary Figure 6: SerpinB2 knockdown suppressed macrophages infiltration into MDA-MB-231<sup>miR-200c/141</sup> cell xenografts.** Macrophage infiltration (F4/80) was observed in MDA-MB-231<sup>miR-200c/141</sup> cell tumors, but decreased in SerpinB2 knockdown tumors.



**Supplementary Figure 7: Correlation between miR-200c, miR-141 and SerpinB2 mRNA in primary TNBC tumor tissues.** SerpinB2 expression was positively correlated with miR-200c and miR-141 expression in TNBC patients (n=19).

Supplementary Table 1: Real-time RT-PCR primer sequences

| Gene     | Accession no.               |         | Sequence (5'→3')        |
|----------|-----------------------------|---------|-------------------------|
| SerpinB2 | NM_001143818                | Forward | CCTGATGCGATTTTGCAGGCGCT |
|          |                             | Reverse | CGCAGACTTCTCACCAA       |
| SerpinE1 | NM_000602                   | Forward | CCCCACTTCTTCAGGCTGTT    |
|          |                             | Reverse | GCCGTTGAAGTAGAGGGCAT    |
| uPA      | NM_001145031<br>NM_002658.3 | Forward | TCCAAGAGTGCATGGTGCAT    |
|          |                             | Reverse | CCTCCACACACGTAGGTGAC    |
| MAL2     | NM_052886NM                 | Forward | CTGGAGATTCTGTTCCGGGGG   |
|          |                             | Reverse | ATTTGAGCCACCATGCCAGA    |
| C15orf54 | NM_207445                   | Forward | AGCCACTCATCACATGACGG    |
|          |                             | Reverse | AGTGCACACACGCTTTGTTG    |
| PLCβ4    | NM_001172646                | Forward | GCGGGTACCTTCTCAAACCA    |
|          |                             | Reverse | GTCAGTGGGCAACCCATACA    |
| MPZL2    | NM_144765                   | Forward | GAGGAAAGGCTCAACCAAGAGA  |
|          |                             | Reverse | TGGTTGGAAAACGGGTCACA    |
| LCP1     | NM_002298                   | Forward | CCTGGCTGATGATTTGTCATTCT |
|          |                             | Reverse | ACCAGGAACCCCTTCTTTCTG   |
| KRTAP2-4 | NM_033184                   | Forward | ATGCCCCACAGAGCAATAC     |
|          |                             | Reverse | GTGGGTGAGGGTGGTAATGG    |
| EDN1     | NM_001955                   | Forward | CACAAAGGCAACAGACCGTG    |
|          |                             | Reverse | GGTCTCCGACCTGGTTTGTG    |
| ID2      | NM_002166                   | Forward | ATGAAAGCCTTCAGTCCCCTG   |
|          |                             | Reverse | GAGCTTGGAGTAGCAGTCGT    |
| EGR1     | NM_001964                   | Forward | CCAACAGTGGCAACACCTTG    |
|          |                             | Reverse | AAATGTCAGTGTTCCGGCGTG   |
| c-Jun    | NM_002228.3                 | Forward | GAGCTGGAGCGCCTGATAAT    |
|          |                             | Reverse | CCCTCCTGCTCATCTGTAC     |
| FosB     | NM_005252.3                 | Forward | GCGCCGGGAACGAAATAAAC    |
|          |                             | Reverse | ACCAGCACAAACTCCAGACG    |
| c-Fos    | NM_006732.2                 | Forward | CGTGCCAGACATGGACCTAT    |
|          |                             | Reverse | CGGGGTAGGTGAAGACGAAG    |



Supplementary Table 2: Relationships between miR-200c/141 expression and clinicopathological features

| Parameters    | No. of cases | miR200c High (%) | miR200c Low (%) | <i>P</i> -value | miR141 High (%) | miR141 Low (%) | <i>P</i> -value |
|---------------|--------------|------------------|-----------------|-----------------|-----------------|----------------|-----------------|
| TNBC          | 21           | 10               | 11              |                 | 10(47.6)        | 11(52.4)       |                 |
| Age           |              |                  |                 |                 |                 |                |                 |
| $\geq 50$     | 9            | 4(44.4)          | 5(55.6)         | 0.80            | 2(22.2)         | 7(77.8)        | 0.04            |
| <50           | 12           | 6(50.0)          | 6(50.0)         |                 | 8(66.7)         | 4(33.3)        |                 |
| Tumor size    |              |                  |                 |                 |                 |                |                 |
| $\geq 2$ cm   | 3            | 1(33.3)          | 2(66.7)         | 0.67            | 2(66.7)         | 1(33.3)        | 0.46            |
| <2 cm         | 18           | 4(22.2)          | 14(77.8)        |                 | 8(44.4)         | 10(55.6)       |                 |
| LN metastasis |              |                  |                 |                 |                 |                |                 |
| Negative      | 11           | 4(36.3)          | 7(63.7)         | 0.27            | 5(45.4)         | 6(54.6)        | 0.83            |
| Positive      | 10           | 6(60.0)          | 4(40.0)         |                 | 5(50.0)         | 5(50.0)        |                 |
| TNM stage     |              |                  |                 |                 |                 |                |                 |
| I-II          | 15           | 7(46.7)          | 8(53.3)         | 0.89            | 6(40.0)         | 9(60.0)        | 0.18            |
| III-IV        | 6            | 3(50.0)          | 3(50.0)         |                 | 4(60.0)         | 2(40.0)        |                 |